Our website is made possible by displaying non-intrusive online advertisements to our visitors.
Please consider supporting us by disabling or pausing your ad blocker.
While foreign patients contribute around 50% of Alpha IVF’s revenue, its niche in offering specialised, high-end in vitro fertilisation treatments suggests that demand will likely remain resilient despite the SST expansion
